secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001437749-24-030557
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma to acquire Increlex from Ipsen for $22.5M upfront plus $7.5M inventory
--------------------------------------------------------------------------------

- Acquisition of Increlex (mecasermin injection) for severe primary IGF-1 deficiency; approved in 40 territories.
- Total upfront consideration $30M ($22.5M asset purchase + $7.5M inventory) plus $2.5M on each of first two anniversaries.
- Credit facility expanded to $30M from SWK Holdings; interest at SOFR+6.75%; 289,736 warrant shares at $5.32.
- Ipsen reported 2023 global sales of €17.3M for Increlex; Eton to immediately commercialize in U.S. after closing.
- Closing expected near year-end 2024; all-cash transaction subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924030557/0001437749-24-030557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924030557/eton20240930_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer